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Introduction {#sec005}
============

Diabetes mellitus (DM) and tuberculosis (TB) are major killers of mankind across the globe \[[@pone.0175925.ref001]\]. The World Health Organization (WHO) global report for 2015 indicates that, there were 10.4 million new cases and 1.4 million deaths resulting from TB \[[@pone.0175925.ref002]\]. In the same year, 415 million cases and 5.0 million deaths due to DM were registered \[[@pone.0175925.ref003]\]. About 95% of TB and 75% of the DM cases live in low- and middle income countries. The rising prevalence of DM is a potential threat to TB control. Poorly controlled DM increases the risk of TB and leads to unfavorable TB treatment outcomes \[[@pone.0175925.ref004]--[@pone.0175925.ref005]\].

WHO has recommended a collaborative framework for the clinical management and control of TBDM comorbidity. Three important intervention strategies namely, establishing mechanisms of collaboration between TB and DM control programs, detection and management of TB in patients with DM, and detection and management of DM in TB patients have been recommended \[[@pone.0175925.ref006]\]. Some countries in Asia (China and India) have piloted the TBDM collaborative framework and have demonstrated that bi-directional screening for both diseases is feasible \[[@pone.0175925.ref007]--[@pone.0175925.ref010]\]. It may also be important if other countries implement this strategy to reduce the dual burden of TBDM comorbidity. However, for policy making and implementation of this strategy, it is crucial to primarily understand the magnitude and associated factors of TBDM comorbidity particularly in low- and middle-income countries.

Former studies conducted in various parts of the world have shown that TBDM comorbidity has become a major public health problem. A wide range of estimates on the burden and associated factors of the two comorbid conditions and impact of DM on TB treatment outcome were reported \[[@pone.0175925.ref011]--[@pone.0175925.ref013]\]. For example, a previous systematic review of bidirectional screening for TBDM comorbidity reported high prevalence of DM among TB patients ranging from 1.9% to 35%. TB prevalence among DM patients ranged from 1.7% to 36% \[[@pone.0175925.ref011]\]. Similarly, another systematic review done on 13 observational studies reported that DM was associated with an increased risk of TB \[relative risk (RR) = 3.11, 95% confidence interval (C.I.) 2.27--4.26\] \[[@pone.0175925.ref012]\]. Several reasons motivated us to do the current systematic review. Firstly, the risk/associated factors of TBDM comorbidity were not included in the previous systematic reviews. Secondly, the numbers of individual studies on TBDM comorbidity conducted after 2010 have increased by 78% compared to the number of studies done before 2010. Thirdly, unlike the periods before six years, bi-directional screenings of TB and DM studies have been emerging from different African countries. Therefore, an updated synthesis of the prevalence and associated factors of the two comorbid conditions is important for policy making, planning and development of TBDM integrated services. This systematic review was thus conducted to summarize the existing evidence on prevalence and associated/risk factors of TBDM comorbidity.

Methods {#sec006}
=======

Eligibility criteria {#sec007}
--------------------

In this systematic review, we included all full text articles that involved human subjects of any age, and that determined either prevalence and risk/associated factors of DM among TB patients or prevalence and associated factors of TB among DM patients. Type of DM was not an inclusion/exclusion criteria and therefore both types were included. Studies reporting prevalence of DM among latent TB patients, prevalence of impaired glucose tolerance among TB patients and incidence of TB among DM patients were excluded from the review. In addition, pharmacological studies related to TBDM comorbid conditions, articles written other than English language, conference papers, abstracts without full texts, articles that didn't describe journal's name and corresponding author, articles that reported prevalence/incidence of the two comorbidity conditions stratified by socio-demographic and clinical parameters were excluded from the study.

Search strategy and selection of studies {#sec008}
----------------------------------------

We searched Ovid Medline from 1946 to March 09/2016, Embase from 1947 to March 09/2016, Global health from1973 to March 09/2016, Cochrane library from 1992- March 09/2016, Web of science from 1900-March 09/2016 and Scopus elsevier from 1996-March 09/2016 using the following medical subject heading (MeSh) and text terms **([Table 1](#pone.0175925.t001){ref-type="table"}).** The full strategy was run in Endnote software. We also used hand searching to look for relevant reference lists and journals.

10.1371/journal.pone.0175925.t001

###### Search strategy from the different data bases.

![](pone.0175925.t001){#pone.0175925.t001g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Data base                                          \# Searches
  -------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ovid MEDLINE(R) 1946 to Mar 09/2016                **1**. exp Diabetes Mellitus/ep, **2**. diabet\*.tw,kf., **3**. 1 or 2, **4**.exp Tuberculosis/ep, **5**. tuberculosis. tw,kf, **6.** 4 or 5, **7**.exp Comorbidity/ or exp Prevalence/ or exp Incidence/ or exp Diagnosis / or exp Risk Factor/ or exp Epidemiology /, **8**. (co-morbid\* or comorbid\* or co-occurren\* or prevalen\* or inciden\* or diagnos\* or screen\* or detect\* or risk\* or epidemiolog\*). tw,kf, **9.** 7 or 8, **10**. exp Cohort Analysis/ or exp Case-Control Study/ or exp Cross-Sectional Study/ or exp Follow-Up Studies/ or exp Longitudinal Study/ or exp Retrospective Study/, **11**. (cohort stud\* or case-control stud\* or cross-sectional stud\* or follow-up stud\* or followup stud\*longitudinal stud\* or retrospective stud\*). tw,kf, **12.** 10 or 11, **13.** 3 and 6 and 9 and 12, **14.** limit 13 to (english language and yr = \"1946 -Current\" Mar 09/2016)

  Ovid Embase Classic+Embase 1947 to Mar 09/2016\    **1.** exp Diabetes Mellitus/ep, **2**. diabet\*. tw,kw., **3.** 1 or 2, **4**. exp Tuberculosis/ep, **5.** tuberculosis. tw,kw., **6.** 4 or 5, **7**. exp Comorbidity/ or exp Prevalence/ or exp Incidence/ or exp Diagnosis / or exp Risk Factor/ or exp Epidemiology /, **8**. (co-morbid\* or comorbid\* or co-occurren\* or prevalen\* or inciden\* or diagnos\* or screen\* or detect\* or risk\* or epidemiolog\*). tw,kw., **9.** 7 or 8, **10**. exp Cohort Analysis/ or exp Case-Control Study/ or exp Cross-Sectional Study/ or exp Follow-Up Studies/ or exp Longitudinal Study/ or exp Retrospective Study/, 1**1**. (cohort stud\* or case-control stud\* or cross-sectional stud\* or follow-up stud\* or followup stud\*longitudinal stud\* or retrospective stud\*). tw,kw., **12.** 10 or 11, **13.** 3 and 6 and 9 and 12, **14.** limit 13 to to (english language and yr **= \"**1947 -Current\" Mar 09/2016)

  Global health 1973 to 2016 Mar 09/2016             **1.** diabet\*.mp., **2.** tuberculosis.mp., **3.** (co-morbid\* or comorbid\* or co-occurren\* or prevalen\* or inciden\* or diagnos\* or screen\* or detect\* or risk\* or epidemiolog\*).mp., **4.** (cohort stud\* or case-control stud\* or cross-sectional stud\* or follow-up stud\* or followup stud\* or longitudinal stud\* or retrospective stud\*).mp., **5.** and/1-4, **6.** limit 5 to (english language and yr = \"1973 -Current\" Mar 09/2016)\

  Cochrane library 1992-present (Mar 09/2016)\       **1.**MeSH descriptor: \[Diabetes Mellitus\] explode all trees, **2.**diabet\*:ti,ab,kw (Word variations have been searched), **3.**MeSH descriptor: \[Tuberculosis\] explode all trees, **4.**tuberculosis:ti,ab,kw (Word variations have been searched), **5**.MeSH descriptor: \[Comorbidity\] explode all trees, **6**.MeSH descriptor: \[Prevalence\] explode all trees, **7.**MeSH descriptor: \[Incidence\] explode all trees, **8**.MeSH descriptor: \[Diagnosis\] explode all trees, **9.**MeSH descriptor: \[Risk Factors\] explode all trees, **10.**MeSH descriptor: \[Epidemiology\] explode all trees, **11.**comorbid\*:ti,ab,kw or co-morbid\*: ti,ab,kw or co-occurren\*: ti,ab,kw or prevalen\*: ti,ab,kw or inciden\*: ti,ab,kw (Word variations have been searched), **12.**diagnos\*: ti,ab,kw or screen\*.ti,ab,kw, or detect\*: ti,ab,kw (Word variations have been searched), **13**.risk\*:ti,ab,kw or epidemilog\*:ti,ab,kw (Word variations have been searched), **14.** ((\#1 or \#2) and (\#3 or \#4) and ({or \#5-\#9} or \#10 or \#11 or\#12))\

      Web of science 1900-present (March 09/2016)\   (TS = (diabet\* AND tuberculosis AND (co-morbid\* OR comorbid\* OR co-occurren\* OR prevalen\* OR inciden\* OR diagnos\* OR screen\* OR detect\* OR risk\* OR epidemiolog\*) AND (cohort stud\* OR case-control stud\* OR cross-sectional stud\* OR follow-up stud\* OR followup stud\* OR longitudinal stud\* OR retrospective stud\*))) *AND* LANGUAGE: (English) *AND* DOCUMENT TYPES: (Article OR Proceedings Paper) *Limiters*: Language: English, *Document* types: Article OR Proceedings Paper\

  Scopus 1996-March 09 /2016\                        (TITLE-ABS-KEY(diabet\*) AND TITLE-ABS-KEY(tuberculosis) AND TITLE-ABS-KEY(co-morbid\* OR comorbid\* OR co-occurren\* OR prevalen\* OR inciden\* OR diagnos\* OR screen\* OR detect\* OR risk\* OR epidemiolog\*) AND TITLE-ABS-KEY(cohort stud\* OR case-control stud\* OR cross-sectional stud\* OR follow-up stud\* OR followup stud\* OR longitudinal stud\* OR retrospective stud\*)) AND (LIMIT-TO(DOCTYPE,\"ar\") OR LIMIT-TO(DOCTYPE,\"cp\")) AND (LIMIT-TO(SUBJAREA,\"MEDI\")) AND (LIMIT-TO(LANGUAGE, \"English\"))\
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data extraction and risk of bias assessment {#sec009}
-------------------------------------------

A standardized form using excel sheet was used to extract relevant information. The standardized form was pilot tested in twenty selected articles included in the study. A number of variables including study locations, years of publications, study periods, study designs, number of patients included in the study, and prevalence of TBDM and associated/risk factors were extracted from all studies included in the systematic review. The risk of bias for each study was assessed using study design, sampling technique and sample size determination methods as important domains. In addition, we considered ''type of screening method used" and ''time of screening" for studies that assessed prevalence of DM among TB patients. For studies that analyzed TB prevalence among DM patients, ''type of TB screening method used" was considered as an important domain **([Table 2](#pone.0175925.t002){ref-type="table"}).** Some of the above domains were also used in the previously conducted systematic review (12).One reviewer (MHW) searched, extracted the data and assessed the risk of bias. Any ambiguity in the extracted and assessed information was resolved through discussion with the other author (SAY).

10.1371/journal.pone.0175925.t002

###### Risk of bias assessment tools.

![](pone.0175925.t002){#pone.0175925.t002g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                                                                                                                                                                                                                        Methods used by the studies                                                                                                                                                                                                                                                                   Risk of bias   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- ---
  Study design                                                                                                                                                                                                                                                                    Prospective cohort, cross-sectional or descriptive, case control, observational, population based study designs                                                                                                                                                                                              0

  Retrospective cohort, record review and studies that did not report study design                                                                                                                                                                                                1                                                                                                                                                                                                                                                                                                            

  Sampling methods                                                                                                                                                                                                                                                                Random selection                                                                                                                                                                                                                                                                                             0

  Consecutive enrollment of all eligible patients & studies that did not describe sampling methods                                                                                                                                                                                1                                                                                                                                                                                                                                                                                                            

  Sample size determination                                                                                                                                                                                                                                                       Sample size determined                                                                                                                                                                                                                                                                                       0

  Sample size not determined or studies that did not report how sample size was estimated                                                                                                                                                                                         1                                                                                                                                                                                                                                                                                                            

  Methods of DM screening among TB patients                                                                                                                                                                                                                                       Use of blood test alone, or use of combination methods (blood test either with urine glucose, self-report or medical record review)                                                                                                                                                                          0

  Studies that reported the use of self- report, urine glucose, record review methods alone or in combination, and studies that did not report methods of DM screening                                                                                                            1                                                                                                                                                                                                                                                                                                            

  Timing of DM screening                                                                                                                                                                                                                                                          Studies that screened at the time of TB diagnosis or before TB treatment was started and both before and after anti-TB treatment was started                                                                                                                                                                 0

  Studies that screened after TB treatment was initiated, or at the middle of TB treatment, or at the end of TB treatment period or both, and studies that did not report timing of DM screening                                                                                  1                                                                                                                                                                                                                                                                                                            

  Methods of TB screening among DM patients                                                                                                                                                                                                                                       Use of WHO or National TB Control Program diagnostic methods of the respective country, use of either combination or individual screening methods of either of the following methods: microbiologically determined (sputum microscopy or sputum culture), PCR, Xpert/RIF-TB test or QFT-G.\                  0
                                                                                                                                                                                                                                                                                  Use of clinical sign and symptoms, response to treatment, chest x-ray, tuberculin skin test, histopathology in combination with one of the above mentioned diagnostic methods                                                                                                                                

  Studies that used ICD code, self-report, medical record review, clinical sign and symptoms, response to treatment, chest x-ray, tuberculin skin test, histopathology, broncho-alveolar lavage alone or in combination and studies that did not report methods of TB screening   1                                                                                                                                                                                                                                                                                                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

0 = low risk, 1 = high risk, DM = diabetes mellitus, TB = tuberculosis, WHO = World Health Organization, PCR = Polymerase chain reaction, Xpert MTB/RIF-TB = GeneXpert Rifampicin-TB, QFT-G = QuantiFERON-TB Gold, ICD = International classification of diseases

Data analysis and syntheses {#sec010}
---------------------------

Descriptive statistics (range and median with interquartile range (IQR)) were used to summarize prevalence rates estimated from individual studies. Due to the observed wide variations in prevalence, and sample sizes used in the reviewed articles, we reported median prevalence rate based on geographical regions. The summaries were described into two groups, i.e. prevalence of DM among TB patients and prevalence of TB among DM patients. Data analyses were performed using Statistical Package for Social Science (SPSS) version 22 Armonk, New York 10504 IBM Corp. The risk/associated factors were grouped into main themes and described accordingly. In addition, findings of the studies were grouped into the different geographical regions of the world depending on where the individual studies were conducted. Each domain assessed for the risk of bias was categorized as either low or high risk of bias depending on the findings of each study. We scored 0 and 1 for low and high risk of bias, respectively. Accordingly, for studies that determined prevalence of DM among TB patients, the overall risk of study bias was calculated out of five total score points. While those with a total point of ≤ 2 were considered low risk, studies with a total value of 3--4 and 5 were considered to have moderate and high risk of bias, respectively. Similarly, for studies that analyzed prevalence of TB among DM patients, the overall risk of study bias was calculated out of four total score points. Consequently, studies that scored a total of ≤1 were considered low risk, and those with a total value of 2 and 3--4 were evaluated to have moderate and high risk of bias, respectively.

Results {#sec011}
=======

A total of 1845 literatures were initially selected for screening. These included 1765 literatures identified from the electronic database search, 59 identified by hand search and 21 literatures identified by reference check **([Fig 1](#pone.0175925.g001){ref-type="fig"}).** After removing 780 duplicate articles form the total 1845 literatures, 1065 articles remained for further screening. **Additional screening** by title and abstract resulted in the exclusion of 877 articles and we were left with 188 articles for further screening. We performed full text screening on 188 articles and found that 94 articles were eligible for final analysis \[[@pone.0175925.ref009]--[@pone.0175925.ref010], [@pone.0175925.ref014]--[@pone.0175925.ref105]\]. The criteria for exclusion of the different studies are listed in [Fig 1](#pone.0175925.g001){ref-type="fig"}.

![Flow diagram of searched articles.\
TB: tuberculosis, DM: diabetes mellitus, MDR: multi drug resistance.](pone.0175925.g001){#pone.0175925.g001}

The 94 studies selected for final analysis had applied different study designs. Majority 36 (38.3%) were cross-sectional studies, 11 (11.7%) were prospective cohort, 9 (9.6%) applied retrospective cohort study design, 21 (22.3%) were medical record reviews, four (4.3%) studies used prospective observational (not clearly specified) method, three (3.2%) used case-controls study design and 10 (10.6%) studies did not describe the type of study design used. The studies represented 33 countries globally and were divided into six regions. Of the total studies included in the analysis, 74 (78.7%) were published between 2011 and 2016, 12 (12.8%) studies were published from 2000 to 2010, and 8 (8.5%) studies were reported between 1957 to 1999 **([Table 3](#pone.0175925.t003){ref-type="table"}).**

10.1371/journal.pone.0175925.t003

###### Profile of reviewed articles.

![](pone.0175925.t003){#pone.0175925.t003g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Region          First author and publication year   Country                               Study period                       Study design                                                                Reference
  --------------- ----------------------------------- ------------------------------------- ---------------------------------- --------------------------------------------------------------------------- ----------------------------
  Asia            India group et al. 2013             India                                 Jan-Sep/2012                       Prospective observational                                                   \[[@pone.0175925.ref009]\]

                  China group et al. 2012             China                                 1 Sep 2011--31 March 2012          Prospective observational                                                   \[[@pone.0175925.ref010]\]

                  Achanta et al. 2013                 Saluru-South India                    Jan--Sep/2012                      Cross-sectional                                                             \[[@pone.0175925.ref014]\]

                  Alavi et al. 2012                   Iran                                  2008--2010                         Medical record review                                                       \[[@pone.0175925.ref015]\]

                  Alisjahbana et al. 2006             Indonesia                             2001--2005                         Case-control                                                                \[[@pone.0175925.ref016]\]

                  Baghaei et al.2015                  Tehran-Iran                           May 2012-May 2013                  Prospective cohort                                                          \[[@pone.0175925.ref017]\]

                  Balakrishnan et al.2012             Kerala-India                          June-July/2011                     Cross-sectional                                                             \[[@pone.0175925.ref018]\]

                  Dave et al. 2013                    Gujarat -India                        Jan-Sep/ 2012                      Cross-sectional                                                             \[[@pone.0175925.ref019]\]

                  Jawad et al. 1995                   Nazimabad-Pakistan                    NR                                 NR                                                                          \[[@pone.0175925.ref020]\]

                  Lin et al. 2015                     Taiwan                                Sep-Nov/2012                       Cross-sectional                                                             \[[@pone.0175925.ref021]\]

                  Pandya et al. 1991                  Riyadh                                July 83-August 87                  Medical record review                                                       \[[@pone.0175925.ref022]\]

                  Raghuraman et al. 2014              Puducherry                            NR                                 Cross-sectional                                                             \[[@pone.0175925.ref023]\]

                  Rajapakshe et al. 2015              SriLanka                              Jan 2013-Oct 2014                  Cross-sectional                                                             \[[@pone.0175925.ref024]\]

                  Shidam et al. 2015                  Pondicherry, India                    Jan- Dec /2013                     Cross-sectional                                                             \[[@pone.0175925.ref025]\]

                  Thapa et al. 2015                   Nepal                                 15^th^ of Sep - 23rd of Nov/2013   Cross-sectional                                                             \[[@pone.0175925.ref026]\]

                  Usmani et al. 2014                  Lahore-Pakistan                       1^st^ July-3oth Sep /2011          Cross-sectional                                                             \[[@pone.0175925.ref027]\]

                  Viswanathan et al. 2012             India                                 Jan-March/2011                     NR                                                                          \[[@pone.0175925.ref028]\]

                  Nagar et al. 2015                   India                                 Oct 2013-March 2014                Cross-sectional                                                             \[[@pone.0175925.ref029]\]

                  Wang et al. 2013                    China                                 Sep 2010-Dec 2012                  Prospective community based cohort                                          \[[@pone.0175925.ref030]\]

                  Sarvamangala et al. 2014            India                                 Jan 2012-Aug 2012                  Cross-sectional                                                             \[[@pone.0175925.ref031]\]

                  Deshmukh et al. 1984                India                                 NR                                 NR                                                                          \[[@pone.0175925.ref032]\]

                  Chachra et al. 2014                 Ghaziabad -India                      NR                                 Cross-sectional                                                             \[[@pone.0175925.ref033]\]

                  Wang et al. 2000                    Taiwan                                1993--1996                         Retrospective cohort                                                        \[[@pone.0175925.ref034]\]

                  Chaudhry et al. 2012                Filipino-Saudi-Arabia                 Jan. 2003-June 2010                Retrospective/medical record                                                \[[@pone.0175925.ref035]\]

                  Duangrithi et al. 2013              Thailand                              April 2010 -July 2012              Prospective                                                                 \[[@pone.0175925.ref036]\]

                  Jabbar et al.2006                   Pakistian                             Jan 1992-Dec 1996                  Retrospective descriptive (Medical record review)                           \[[@pone.0175925.ref037]\]

                  Jali et al. 2013                    India                                 Feb-Sep/2012                       Cross-sectional                                                             \[[@pone.0175925.ref038]\]

                  Magee et al. 2015                   Georgia- Tbilisi                      Oct 2011-May 2014                  Prospective cohort                                                          \[[@pone.0175925.ref039]\]

                  Mi et al. 2013                      Guangzhou, China                      1 Sep. 2011--30 June 2012          Cross-sectional and retrospective cohort study (medical record review)      \[[@pone.0175925.ref040]\]

                  Mi et al. 2014                      Bejing -China                         1 Jan 2011--30 June 2012           Cross-sectional and retrospective record review                             \[[@pone.0175925.ref041]\]

                  Pablo-Villamor et al.2014           Philippines                           July 2011-Nov.2012                 Prospective observational cohort study                                      \[[@pone.0175925.ref042]\]

                  Park et al.2012                     Korea                                 Jan 2005-Dec 2009                  Retrospective (medical record review)                                       \[[@pone.0175925.ref043]\]

                  Roghieh et al. 2011                 Iran                                  2004--2008                         Retrospective cross-sectional (review of medical record)                    \[[@pone.0175925.ref044]\]

                  Mehta et al. 2015                   India                                 2012--2013                         Cross-sectional                                                             \[[@pone.0175925.ref045]\]

                  Shaikh et al. 2003                  Saudi-Arabia                          Jan1998-Dec1999                    Retrospective (medical record)                                              \[[@pone.0175925.ref046]\]

                  Siddiqui et al. 2009                Saudi-Arabia                          Jan 2002-Dec 2007                  Retrospective (medical record review)                                       \[[@pone.0175925.ref047]\]

                  Sulaiman et al. 2013                Malaysia                              Jan 2006-Dec 2007                  Retrospective cohort                                                        \[[@pone.0175925.ref048]\]

                  Zhang et al. 2009                   China                                 2008--2009                         Retrospective                                                               \[[@pone.0175925.ref049]\]

                  Chen et al. 2014                    China                                 Jan 2010-Dec 2011                  Cross-sectional                                                             \[[@pone.0175925.ref050]\]

                  Jali et al. 2013                    India                                 Feb 2012-Sep 2012                  Prospective observational study                                             \[[@pone.0175925.ref051]\]

                  Kumpatla et al. 2013                India                                 Mar-Dec/ 2012                      Descriptive (review of record)                                              \[[@pone.0175925.ref052]\]

                  Tripathy et al. 1984                India                                 1^st^ Jan. 1978- 31^st^ Dec.1982   Prospective study                                                           \[[@pone.0175925.ref053]\]

                  Wu et al. 2015                      China                                 2007--2008                         Retrospective population based study                                        \[[@pone.0175925.ref054]\]

                  Naeem et al. 2016                   Pakistan                              Feb 2013-Dec 2014                  Prospective observational                                                   \[[@pone.0175925.ref055]\]

                  Nair et al. 2013                    Kerala-India                          March-Sep/2012                     Descriptive study                                                           \[[@pone.0175925.ref056]\]

                  Tahir et al.2014                    Kohat-Pakistan                        NR                                 Cross-sectional                                                             \[[@pone.0175925.ref057]\]

                  Jain et al. 2015                    India                                 NR                                 Cross-sectional                                                             \[[@pone.0175925.ref058]\]

                  Amin et al. 2011                    Pakistan                              1^st^ Aug 2010-31st July 2011      NR                                                                          \[[@pone.0175925.ref059]\]

                  Prakash et al.2013                  India                                 1 March-30 Sep 2012                Descriptive study                                                           \[[@pone.0175925.ref060]\]

                  Qayyum et al.2004                   Pakistan                              Jan.2001 --Dec 2001                NR                                                                          \[[@pone.0175925.ref061]\]

                  Sangral et al. 2012                 Jammu-India                           2009--2010                         NR                                                                          \[[@pone.0175925.ref062]\]

                  Alisjahbana et al. 2007             Indonesia                             Oct 2000-Dec 2005                  Prospective cohort                                                          \[[@pone.0175925.ref063]\]

                  Kermansaravi et al. 2014            Iran                                  April 2010-Dec 2011                Cross-sectional                                                             \[[@pone.0175925.ref064]\]

                  Padmalatha et al. 2014              India                                 May 2014-Oct 2014                  Cross-sectional                                                             \[[@pone.0175925.ref065]\]

                  Kottarath et al. 2015               Kerala-India                          Aug.2014-July 2015                 Descriptive                                                                 \[[@pone.0175925.ref066]\]

                  Rao et.al 2015                      Hyderabad-India                       June-July/ 2014                    Cross-sectional                                                             \[[@pone.0175925.ref067]\]

  Africa          Ade et al. 2015                     Cotonou-Benin                         June-July/ 2014                    Cross-sectional                                                             \[[@pone.0175925.ref068]\]

                  Amare et al. 2013                   Ethiopia                              Feb-April/ 2012                    Cross-sectional                                                             \[[@pone.0175925.ref069]\]

                  Faurholt-Jepsen et al. 2011         Tanzania                              April 2006-Jan 2009                Case control                                                                \[[@pone.0175925.ref070]\]

                  Haraldsdottir et al. 2015           Guinea-Bissau                         July 2010-July 2011                NR                                                                          \[[@pone.0175925.ref071]\]

                  Kibirige et al. 2013                Uganda                                Sep 2011- Feb 2012                 Cross-sectional                                                             \[[@pone.0175925.ref072]\]

                  Mtwangambate et al. 2014            Tanzania                              Sep 2011-March 2012                Prospective cohort                                                          \[[@pone.0175925.ref073]\]

                  Ogbera et al. 2014                  Lagos-Nigeria                         Sep 2010 --March 2012              Cross-sectional                                                             \[[@pone.0175925.ref074]\]

                  Olayinka et al. 2013                Lagos-Nigeria                         NR                                 Cross-sectional                                                             \[[@pone.0175925.ref075]\]

                  Workneh et al.2016                  Ethiopia                              Sep 2103 --Sep 2014                Cross-sectional                                                             \[[@pone.0175925.ref076]\]

                  Feleke et al. 1999                  Ethiopia                              Sep 1989--1996                     Cross-sectional based on the retrospective analysis of data review record   \[[@pone.0175925.ref077]\]

                  Swai et al. 1990                    Tanzania                              1 June 1981--31 May 1977           NR                                                                          \[[@pone.0175925.ref078]\]

                  Webb et al. 2009                    South -Africa                         10 Sept 2006--31 Jan 2007          Cross-sectional                                                             \[[@pone.0175925.ref079]\]

                  Kirui et al. 2012                   Kenya                                 Jan 2007-Feb 2011                  Descriptive study from routine record data                                  \[[@pone.0175925.ref080]\]

                  Tiroro et al. 2015                  Ethiopia                              Jan 2010-Jan 2014                  Retrospective study (medical record)                                        \[[@pone.0175925.ref081]\]

                  Ogbera et al. 2015                  Lagos-Nigeria                         March 2011-July 2012               Descriptive observational study                                             \[[@pone.0175925.ref082]\]

                  Getachew et al. 2014                Ethiopia                              Oct.2011-August 2012               Cross-sectional                                                             \[[@pone.0175925.ref083]\]

                  Damtew et al. 2014                  Ethiopia                              Feb.2014-May 2014                  Cross-sectional                                                             \[[@pone.0175925.ref084]\]

                  Balad et al. 2006                   Guinea                                1 Feb 30 -June 2002                NR                                                                          \[[@pone.0175925.ref085]\]

                  Rakotonirina et al. 2014            Antananarivo-Madagascar               July15,2013---Oct.30,2013          Descriptive                                                                 \[[@pone.0175925.ref086]\]

                  Mugusi et al. 1990                  Tanzania                              NR                                 NR                                                                          \[[@pone.0175925.ref087]\]

  Europe          Moreno-Mart´ınez et al. 2015        European city- Barcelona              1 Jan 2000--31 Dec 2013            Retrospective, population\                                                  \[[@pone.0175925.ref088]\]
                                                                                                                               based cross-sectional                                                       

                  Warwick et al. 1957                 Britain                               1 Jan 1940-Dec 31,1954             Medical record review                                                       \[[@pone.0175925.ref089]\]

  North America   Ponce-de-leon et al. 2004           Mexico                                1995--2003                         Population based cohort study                                               \[[@pone.0175925.ref090]\]

                  Restrepo et al. 2007                Texas-Mexico                          Mexico (1998--2003) /\             Medical record review                                                       \[[@pone.0175925.ref091]\]
                                                                                            Texas (1996--2002)                                                                                             

                  Restrepo et al. 2011                South-Texas & North -eastern Mexico   March 2006-Sep 2008                Cross-sectional                                                             \[[@pone.0175925.ref092]\]

                  Magee et al. 2014                   Georgia-US                            Jan 2009- Sep 2012                 Retrospective cohort                                                        \[[@pone.0175925.ref093]\]

                  Suwanpimolkul et al.2014            USA-San Francisco                     April 2005-March 2012              Retrospective                                                               \[[@pone.0175925.ref094]\]

                  Delgado-Sánchez et al. 2015         Mexico                                2000--2012                         TB registry review retrospective analysis                                   \[[@pone.0175925.ref095]\]

                  Castellanos-Joya et al. 2014        Mexico                                July 2012---April 2013             Prospective observational cohort                                            \[[@pone.0175925.ref096]\]

                  Jiménez-Corona et al. 2013          Southern -Mexico                      1995 to 2010                       Prospective cohort                                                          \[[@pone.0175925.ref097]\]

  South America   Alladin et.al. 2011                 Guyana                                May-June/2006                      Cross-sectional                                                             \[[@pone.0175925.ref098]\]

                  Magee et al. 2013                   Peru                                  Jan.2005-May 2008                  Medical record                                                              \[[@pone.0175925.ref099]\]

                  Reis-Santos et al. 2013             Brazil                                2009                               Disease notification information system                                     \[[@pone.0175925.ref100]\]

  Oceania         Bridison et al. 2015                Australia                             1995--2014                         Retrospective                                                               \[[@pone.0175925.ref101]\]

                  Viney et al. 2015                   Kiribati-Pacific Island               June 2010-March 2012               Case control (unmatched)                                                    \[[@pone.0175925.ref102]\]

                  Nasa et. al. 2014                   Ebeye-Marshall Islands                July 2010-Dec 2012                 Retrospective cohort                                                        \[[@pone.0175925.ref103]\]

                  Prasad et al. 2014                  Fiji                                  2010--2012                         Retrospective descriptive (TB register)                                     \[[@pone.0175925.ref104]\]

                  Gounder et al. 2012                 Fiji                                  Jan-March/2012                     Cross-sectional medical record review                                       \[[@pone.0175925.ref105]\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR = Not reported, TB = tuberculosis.

Risk of bias {#sec012}
------------

The value of risk of bias ranged from 1 to 5 for 78 studies that determined prevalence of DM among TB patients. Based on this assessment, 23 (29.5%) studies were assessed to have low risk of bias, 49 (62.8%) studies had moderate risk of bias and 6 (7.7%) studies were evaluated as having high risk of bias. The risk of bias for 19 studies that analyzed prevalence of TB among DM patients ranged from 0 to 4. Accordingly, 3 (15.8%) studies were assessed to have low risk of bias, 8 (42.1%) studies were evaluated as having moderate risk of bias and 8 (42.1%) studies were assessed to have high risk of bias **(-[S1 Table](#pone.0175925.s002){ref-type="supplementary-material"}. Assessment of risk of bias of the studies).**

Prevalence of DM among TB patients {#sec013}
----------------------------------

Out of the total 94 studies, 78 studies reported DM prevalence among TB patients. Except one study, all reported the total number of observed DM cases among enrolled TB patients. Accordingly, the prevalence of DM among TB patients ranged from 1.9% in Cotonou-Benin to 45% in Ebeye-Marshall Islands \[[@pone.0175925.ref068],[@pone.0175925.ref103]\]. This amounted to an overall global median DM prevalence of 16% (IQR 9.0--25.3%). Among the 78 studies, 48 (61.5%) studies were conducted in countries of Asia and showed prevalence rates ranging from 5.1% in Saluru-South India to 44% in Kerala-India \[[@pone.0175925.ref014], [@pone.0175925.ref018]\]. The overall median prevalence of DM among TB patients in Asia was calculated to be 17% (IQR 11.4%-25.8%). Thirteen (16.7%) studies conducted in countries of Africa showed prevalence rates ranging from 1.9% in Cotonou-Benin to 16.7% in Tanzania \[[@pone.0175925.ref068], [@pone.0175925.ref070]\]. This resulted in an overall median prevalence of 6.7% (IQR 4.1%-10.4%) in the studied countries of Africa. Eight (10.3%) studies that were done in countries of North America showed a prevalence rates ranging from 11.4% in Georgia \[[@pone.0175925.ref093]\] to 39.0% in South Texas \[[@pone.0175925.ref092]\]. The median prevalence in North America was 23.6% (IQR 17.3%-35.4%). There were five (6.4%) studies from Oceania that showed prevalence rates ranging from 12% in Fiji \[[@pone.0175925.ref104]\] to 45% in Ebeye-Marshall Islands \[[@pone.0175925.ref103]\] and the overall median prevalence in this area was 23.2% (IQR 12.8%-39.0%). Three (3.8%) studies conducted in South America indicated prevalence rates ranging from 6.1% in Brazil to 14% in Guyana \[[@pone.0175925.ref098],[@pone.0175925.ref101]\]. This amounted to an overall median prevalence of 11.1% (IQR 6.1%-14.0%). There was only one study from Europe that showed a prevalence rate of 5.9% **([Fig 2](#pone.0175925.g002){ref-type="fig"}).**

![Map showing median prevalence of DM among TB patients by region.\
(NB: There is only one study reported in Europe). IQR: Interquartile range (Source of the map: <https://www.flickr.com/photos/blatantworld/5052373414#>. Accessed March 20/2017).](pone.0175925.g002){#pone.0175925.g002}

Of the 78 studies included in this systematic review, only ten (12.8%) studies reported number needed to screen (NNS). The NNS indicates the number of TB patients that must be screened to get a single case of DM. The NNS ranged from four cases in Kerala India \[[@pone.0175925.ref018]\] to 56 in SriLanka \[[@pone.0175925.ref023]\]. Only 42 (53.8%) studies described the number of new DM patients obtained by screening TB patients. The number of new DM cases obtained after screening ranged from one case in Cotonou-Benin \[[@pone.0175925.ref068]\] to 402 cases in India \[[@pone.0175925.ref009]\] **([Table 4](#pone.0175925.t004){ref-type="table"}).**

10.1371/journal.pone.0175925.t004

###### Prevalence of TBDM comorbidity.

![](pone.0175925.t004){#pone.0175925.t004g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Region          First author and publication year   Country                    Prevalence of DM among TB patients   Prevalence of TB among DM patients   Reference                                                                                                        
  --------------- ----------------------------------- -------------------------- ------------------------------------ ------------------------------------ --------------------------- ------------ ----------------- ------ ---------------- ----- ----------------- ----- ------------------------------------------------------------------
  Asia            India group et al. 2013             India                      8109                                 1084                                 13                          402 (5)      682 (8)           NR                                                    \[[@pone.0175925.ref009]\]

                  China group et al. 2012             China                      8886                                 1090                                 12.4                        227 (2.9 )   863 (9.7 )        NR                                                    \[[@pone.0175925.ref010]\]

                  Achanta et al. 2013                 Saluru-South India         374                                  19                                   5.1                         12 (3.2)     7 (1.9)           31                                                    \[[@pone.0175925.ref014]\]

                  Alavi et al. 2012                   Iran                       148                                  36                                   24.3                        NR           36 (24.3)         NR                                                    \[[@pone.0175925.ref015]\]

                  Alisjahbana et al. 2006             Indonesia                  454                                  60                                   13.2                        36 (60.0)    24 (40)           NR                                                    \[[@pone.0175925.ref016]\]

                                                                                 556 Non-TB control                   18                                   3.2                         12 (66.7)                                                                            

                  Baghaei et al.2015                  Tehran-Iran                293                                  101                                  34.5                        45 (15.4)    56 (19.1)         5                                                     \[[@pone.0175925.ref017]\]

                  Balakrishnan et al.2012             Kerala-India               552                                  243                                  44                          115 (21)     128 (23)          4                                                     \[[@pone.0175925.ref018]\]

                  Dave et al. 2013                    Gujarat -India             553                                  36                                   6.5                         22 (4)       14 (2.5)          25                                                    \[[@pone.0175925.ref019]\]

                  Jawad et al. 1995                   Nazimabad-Pakistan         106                                  21                                   19.8\                       NR           NR                NR                                                    \[[@pone.0175925.ref020]\]

                  Lin et al. 2015                     Taiwan                                                                                                                                                                 3,087            12    0.38              NR    \[[@pone.0175925.ref021]\]

                  Pandya et al. 1991                  Riyadh                     1566                                 136                                  8.7                         NR           NR                NR                                                    \[[@pone.0175925.ref022]\]

                  Raghuraman et al. 2014              Puducherry                 217                                  63                                   29                          18 (8.3)     45 (20.7)         NR                                                    \[[@pone.0175925.ref023]\]

                  Rajapakshe et al. 2015              SriLanka                   112                                  10                                   9                           2 (1.8)      8 (7.1)           56                                                    \[[@pone.0175925.ref024]\]

                  Shidam et al. 2015                  Pondicherry, India         570                                  121                                  21.2\                       52\          69 (57)           11                                                    \[[@pone.0175925.ref025]\]
                                                                                                                                                           (95% CI 18.0--\             (43)                                                                                 
                                                                                                                                                           24.7)                                                                                                            

                  Thapa et al. 2015                   Nepal                      407                                  37                                   9.1                         9 (2.2)      28 (6.9)          NR                                                    \[[@pone.0175925.ref026]\]

                  Usmani et al. 2014                  Lahore-Pakistan            158                                  41                                   25.9                        9 (5.69)     32 (20.3)         NR                                                    \[[@pone.0175925.ref027]\]

                  Viswanathan et al. 2012             India                      827                                  209                                  25.3                        77 (9.3)     132 (15.96)       NR                                                    \[[@pone.0175925.ref028]\]

                  Nagar et al. 2015                   India                      220                                  34                                   15.4                        9 (4.09)     25 (11.3)         NR                                                    \[[@pone.0175925.ref029]\]

                  Wang et al. 2013                    China                      6382                                 403                                  6.3                         177 (43.9)   NR                NR                                                    \[[@pone.0175925.ref030]\]

                                                                                 6675 Non-TB controls                 313                                  4.7                         136 (43.5)   NR                NR                                                    

                  Sarvamangala et al. 2014            India                      200                                  28                                   14                          NR           18 (64.3)         NR                                                    \[[@pone.0175925.ref031]\]

                  Deshmukh et al. 1984                India                      2434                                 138                                  5.6                         78 (56.6)    60 (43.4)         NR                                                    \[[@pone.0175925.ref032]\]

                  Chachra et al. 2014                 Ghaziabad -India           700                                  88                                   12.6                        64 (72.7)    24 (27.3)         NR                                                    \[[@pone.0175925.ref033]\]

                  Wang et al. 2000                    Taiwan                     2841                                 480                                  16.9                        NR           NR                NR                                                    \[[@pone.0175925.ref034]\]

                  Chaudhry et al. 2012                Filipino-Saudi -Arabia     1388                                 114                                  7.17                        NR           NR                NR                                                    \[[@pone.0175925.ref035]\]

                  Duangrithi et al. 2013              Thailand                   227                                  37                                   16.3                        11 (29.7)    26 (70.3)         NR                                                    \[[@pone.0175925.ref036]\]

                  Jabbar et al.2006                   Pakistan                                                                                                                                                               1458             173   11.9              NR    \[[@pone.0175925.ref037]\]

                                                                                                                                                                                                                             Non-DM 40,9000   691   1.7                     

                  Jali et al. 2013                    India                      307                                  109                                  35.5                        NR           NR                NR                                                    \[[@pone.0175925.ref038]\]

                  Magee et al. 2015                   Georgia- Tbilisi           318                                  37                                   11.6 (95% C.I. 8.4--15.5)   9 (24.3)     NR                NR                                                    \[[@pone.0175925.ref039]\]

                  Mi et al. 2013                      Guangzhou, China           1589                                 189                                  12                          NR           NR                NR                                                    \[[@pone.0175925.ref040]\]

                  Mi et al. 2014                      Bejing -China              621                                  187                                  30                          NR           NR                NR                                                    \[[@pone.0175925.ref041]\]

                  Pablo-Villamor et al.2014           Philippines                38                                   7                                    18.4\                       NR           NR                NR                                                    \[[@pone.0175925.ref042]\]
                                                                                                                                                           (95% C.I. 7.7--34.3)                                                                                             

                  Park et al.2012                     Korea                      492                                  124                                  25.2                        NR           NR                NR                                                    \[[@pone.0175925.ref043]\]

                  Roghieh et al. 2011                 Iran                       200                                  80                                   40                          NR           NR                NR                                                    \[[@pone.0175925.ref044]\]

                  Mehta et al. 2015                   India                      194                                  22                                   11.3                        NR           NR                NR                                                    \[[@pone.0175925.ref045]\]

                  Shaikh et al. 2003                  Saudi-Arabia               692                                  187                                  27                          23 (12.3)    NR                NR                                                    \[[@pone.0175925.ref046]\]

                                                                                                                      505 controls without DM                                                                                                                               

                  Siddiqui et al. 2009                Saudi-Arabia               216                                  35                                   16                          NR           NR                NR                                                    \[[@pone.0175925.ref047]\]

                  Sulaiman et al. 2013                Malaysia                   1267                                 338                                  26.7                        NR           NR                NR                                                    \[[@pone.0175925.ref048]\]

                  Zhang et al. 2009                   China                      2141                                 203                                  9.5                         NR           NR                NR                                                    \[[@pone.0175925.ref049]\]

                  Chen et al. 2014                    China                      1126                                 182                                  16.2                        18 (1.6)     164 (14.6)        NR                                                    \[[@pone.0175925.ref050]\]

                  Jali et al. 2013                    India                      307                                  109                                  35.5                        49\          60 (19.54)        NR     4118             111   2.70              NR    \[[@pone.0175925.ref051]\][\*](#t004fn001){ref-type="table-fn"}
                                                                                                                                                                                       (15.96 )                                                                             

                  Kumpatla et al. 2013                India                                                                                                                                                                  7083             50    0.7               NR    \[[@pone.0175925.ref052]\]

                  Tripathy et al. 1984                India                                                                                                                                                                  219              9     4.1               NR    \[[@pone.0175925.ref053]\]

                  Wu et al. 2015                      China                      201                                  40                                   19.90                       NR           NR                NR                                                    \[[@pone.0175925.ref054]\]

                  Naeem et al. 2016                   Pakistan                   95                                   17                                   16.75                       NR           NR                NR                                                    \[[@pone.0175925.ref055]\]

                  Nair et al. 2013                    Kerala-India               920                                  298                                  32.4                        63 (7)       235 (26)          NR                                                    \[[@pone.0175925.ref056]\]

                  Tahir et al.2014                    Kohat-Pakistan             253                                  48                                   18.97                       NR           NR                NR                                                    \[[@pone.0175925.ref057]\]

                  Jain et al. 2015                    India                      189                                  41                                   21.69                       NR           NR                NR                                                    \[[@pone.0175925.ref058]\]

                  Amin et al. 2011                    Pakistian                                                                                                                                                              100              14    14                NR    \[[@pone.0175925.ref059]\]

                  Prakash et al.2013                  India                      510                                  47                                   9.2                         15 (2.9 )    32 (6.3)          16     1670             47    2.8               812   \[[@pone.0175925.ref060]\][\*](#t004fn001){ref-type="table-fn"}

                  Qayyum et al.2004                   Pakistan                                                                                                                                                               95               9     9.5               NR    \[[@pone.0175925.ref061]\]

                                                                                                                                                                                                                             96 Non-DM        2     2.08                    

                  Sangral et al. 2012                 Jammu-India                280                                  23                                   8.2                         NR           NR                NR                                                    \[[@pone.0175925.ref062]\]

                  Alisjahbana et al. 2007             Indonesia                  634                                  94                                   14.8                        57 (61.3)    NR                NR                                                    \[[@pone.0175925.ref063]\]

                  Kermansaravi et al. 2014            Iran                                                                                                                                                                   400              1     1                 NR    \[[@pone.0175925.ref064]\]

                  Padmalatha et al. 2014              India                      252                                  77                                   30.60                       60 (77.8)    17 (22.2)         NR                                                    \[[@pone.0175925.ref065]\]

                  Kottarath et al. 2015               Kerala -India              147                                  29                                   19.7                        16 (55)      13 (45)           NR                                                    \[[@pone.0175925.ref066]\]

                  Rao et.al 2015                      Hyderabad-India                                                                                                                                                        96               10    10                NR    \[[@pone.0175925.ref067]\]

  Africa          Ade et al. 2015                     Cotonou-Benin              159                                  3                                    1.9                         1 (0.63)     2 (1.26)          NR                                                    \[[@pone.0175925.ref068]\]

                  Amare et al. 2013                   Ethiopia                                                                                                                                                               225              14    6.2               NR    \[[@pone.0175925.ref069]\]

                  Faurholt-Jepsen et al. 2011         Tanzania                   803                                  NR                                   16.7\                       NR           NR                NR                                                    \[[@pone.0175925.ref070]\]
                                                                                                                                                           (95% C.I. 14.2--19.4)                                                                                            

                                                                                 350 Non-TB control                   NR                                   9.4\                                                                                                             
                                                                                                                                                           (95% C.I. 6.6--13.0)                                                                                             

                  Haraldsdottir et al. 2015           Guinea-Bissau              107                                  3                                    2.8                         NR           NR                NR                                                    \[[@pone.0175925.ref071]\]

                                                                                 531\                                 11                                   2.1                                                                                                              
                                                                                 Non- TB\                                                                                                                                                                                   
                                                                                 control                                                                                                                                                                                    

                  Kibirige et al. 2013                Uganda                     260                                  22                                   8.5                         NR           5 (1.9)           NR                                                    \[[@pone.0175925.ref072]\]

                  Mtwangambate et al. 2014            Tanzania                                                                                                                                                               693              9\    1.3               NR    \[[@pone.0175925.ref073]\]

                  Ogbera et al. 2014                  Lagos-Nigeria              3376                                 162                                  4.8                         85 (52.5)    77 (47.5)         NR                                                    \[[@pone.0175925.ref074]\]

                  Olayinka et al. 2013                Lagos-Nigeria              351                                  20                                   5.7                         10 (2.8)     NR                NR                                                    \[[@pone.0175925.ref075]\]

                  Workneh et al.2016                  Ethiopia                   1314                                 109                                  8.3                         64 (4.9)     45 (3.4)          19.8                                                  \[[@pone.0175925.ref076]\]

                  Feleke et al. 1999                  Ethiopia                                                                                                                                                               1352             78    5.8               NR    \[[@pone.0175925.ref077]\]

                  Swai et al. 1990                    Tanzania                                                                                                                                                               1250             70    5.6               NR    \[[@pone.0175925.ref078]\]

                  Webb et al. 2009                    South -Africa                                                                                                                                                          258              9\    3.48              NR    \[[@pone.0175925.ref079]\]

                  Kirui et al. 2012                   Kenya                                                                                                                                                                  1376             77    5.6               NR    \[[@pone.0175925.ref080]\]

                  Tiroro et al. 2015                  Ethiopia                                                                                                                                                               681              26    3.8\              NR    \[[@pone.0175925.ref081]\]
                                                                                                                                                                                                                                                    (95% C.I. 2.5-\         
                                                                                                                                                                                                                                                    5.3)                    

                  Ogbera et al. 2015                  Lagos-Nigeria              4000                                 480                                  12.3                        310 (7.7)    170 (4.3)         NR                                                    \[[@pone.0175925.ref082]\]

                  Getachew et al. 2014                Ethiopia                   199                                  17                                   8.5\                        9 (53)       NR                NR                                                    \[[@pone.0175925.ref083]\]
                                                                                                                                                           (95% C.I. 4.6--12.5)                                                                                             

                  Damtew et al. 2014                  Ethiopia                   120                                  19                                   15.8\                       16 (84.2 )   3 (15.8 )         NR                                                    \[[@pone.0175925.ref084]\]
                                                                                                                                                           (95% C.I. 9.20--22.45)                                                                                           

                  Balad et al. 2006                   Guinea                     388                                  13                                   3.35\                       4 (31)       NR                NR                                                    \[[@pone.0175925.ref085]\]
                                                                                                                                                           (95% C.I. 1.35--5.35)                                                                                            

                  Rakotonirina et al. 2014            Antananarivo-Madagascar    156                                  9                                    5.8\                        NR           4 (2.6)           NR                                                    \[[@pone.0175925.ref086]\]
                                                                                                                                                           (95% C.I. 3.1--10.6)                                                                                             

                  Mugusi et al. 1990                  Tanzania                   506                                  34                                   6.7                         25 (4.9)     9 (1.8)           NR                                                    \[[@pone.0175925.ref087]\]

  Europe          Moreno-Mart´ınez et al. 2015        European city- Barcelona   5849                                 349                                  5.9                         NR           NR                NR                                                    \[[@pone.0175925.ref088]\]

                  Warwick et al. 1957                 Britain                                                                                                                                                                1851             34    1.82              NR    \[[@pone.0175925.ref089]\]

  North America   Ponce-de-leon et al. 2004           Mexico                     525                                  185                                  35.2                        NR           NR                NR                                                    \[[@pone.0175925.ref090]\]

                  Restrepo et al. 2007                Texas                      1441                                 401                                  27.8                        NR           401\              NR                                                    \[[@pone.0175925.ref091]\]
                                                                                                                                                                                                    (27.8)                                                                  

                                                      Mexico                     3411                                 607                                  17.8                        NR           607 (17.8)                                                              

                  Restrepo et al. 2011                South-Texas                61                                   24                                   39.0                        NR           NR                NR                                                    \[[@pone.0175925.ref092]\]

                                                      North -eastern Mexico      172                                  62                                   36.0                        NR           NR                NR                                                    

                  Magee et al. 2014                   Georgia-US                 1325                                 151                                  11.4                        NR           NR                NR                                                    \[[@pone.0175925.ref093]\]

                  Suwanpimolkul et al.2014            USA-San Francisco          791                                  126                                  15.9                        NR           NR                NR                                                    \[[@pone.0175925.ref094]\]

                  Delgado-Sánchez et al. 2015         Mexico                     181,378                              34,988                               19.29                       NR           34,988 (19.29 )   NR                                                    \[[@pone.0175925.ref095]\]

                  Castellanos-Joya et al. 2014        Mexico                     361                                  70                                   19.4                        16 (22.9 )   NR                22     783              38    4.9               71    \[[@pone.0175925.ref096]\][\*](#t004fn001){ref-type="table-fn"}

                  Jiménez-Corona et al. 2013          Southern -Mexico           1262                                 400                                  31.7                        26 (2.1)     374 (29.6)        NR                                                    \[[@pone.0175925.ref097]\]

  South America   Alladin et.al. 2011                 Guyana                     100                                  14                                   14                          2 (14.3)     12 (85.7)         NR                                                    \[[@pone.0175925.ref098]\]

                  Magee et al. 2013                   Peru                       1671                                 186                                  11.1                        NR           NR                NR                                                    \[[@pone.0175925.ref099]\]

                  Reis-Santos et al. 2013             Brazil                     29,275                               1797                                 6.1\                        NR           NR                NR                                                    \[[@pone.0175925.ref100]\]
                                                                                                                                                           (95% C.I. 5.9--6.4)                                                                                              

  Oceania         Bridison et al. 2015                Australia                  69                                   16                                   23.2                        NR           NR                NR                                                    \[[@pone.0175925.ref101]\]

                  Viney et al. 2015                   Kiribati-Pacific Island    275                                  101                                  37                          47 (17.1)    54 (19.6)         5                                                     \[[@pone.0175925.ref102]\]

                                                                                 499 control                          94                                   19                          61 (12)      33 (7.0)          8                                                     

                  Nasa et. al. 2014                   Ebeye-Marshall Islands     62                                   28                                   45                          NR           NR                NR                                                    \[[@pone.0175925.ref103]\]

                  Prasad et al. 2014                  Fiji                       567                                  68                                   12                          8 (11.8)     26 (38.2)         NR                                                    \[[@pone.0175925.ref104]\][^θ^](#t004fn002){ref-type="table-fn"}

                  Gounder et al. 2012                 Fiji                       138                                  18                                   13                          NR           18 (13)           NR                                                    \[[@pone.0175925.ref105]\]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* = bidirectional screening studies results

^θ^ = the types of DM status information for 34 (50%) patients was not documented

DM = diabetes mellitus, TB = tuberculosis, NNS = number needed to screen, NR = not reported, C.I. = confidence interval.

Prevalence of TB among DM patients {#sec014}
----------------------------------

Out of the total 94 studies, 19 studies reported TB prevalence among DM patients. The studies were conducted in11 countries distributed in four geographic regions of the world. The prevalence of TB among DM patients ranged from 0.38% in Taiwan \[[@pone.0175925.ref021]\] to 14% in Pakistan \[[@pone.0175925.ref059]\], and the overall median prevalence was 4.1% (IQR 1.8%-6.2%). Among the 19 studies, ten (52.6%) were from four countries of the Asian Region and the prevalence ranged from 0.38% in Taiwan \[[@pone.0175925.ref021]\] to 14% in Pakistan \[[@pone.0175925.ref059]\]. This amounted to an overall median TB prevalence of 3.5% (IQR 0.9%-10.5%) among DM patients in the studied countries of Asian Region. Seven (36.8%) prevalence studies were conducted in four countries of the African Region, and the prevalence ranged from 1.3% in Tanzania \[[@pone.0175925.ref073]\] to 6.2% in Ethiopia \[[@pone.0175925.ref069]\]. The overall median TB prevalence among DM patients in the Africa studies was 5.6% (IQR 3.5%-5.8%). There was only one study in North America (Mexico) that showed a prevalence rate of 4.9% \[[@pone.0175925.ref096]\]. There was also one prevalence study from Europe that showed prevalence rate of 1.82% \[[@pone.0175925.ref089]\] **([Fig 3](#pone.0175925.g003){ref-type="fig"}).** Only two study reported the NNS and NNS reported to screen DM patients to get one TB case ranges 71 DM patients in Mexico\[[@pone.0175925.ref096]\] to 812 in India **\[[@pone.0175925.ref060]\] ([Table 4](#pone.0175925.t004){ref-type="table"}).**

![Map showing median prevalence of TB among DM patients by region.\
(NB: North America and Europe each reported only one study). IQR: Interquartile range (Source of the map: <http://www.sawyoo.com/postpic/2015/02/what-are-the-7-seven-continents_118851.png>. Accessed March 20/2017).](pone.0175925.g003){#pone.0175925.g003}

Risk factors for TBDM comorbidity {#sec015}
---------------------------------

The risk/associated factors for TBDM comorbidity were heterogeneous. Both sexes, age, family history of DM, pulmonary form of TB (PTB) and positive sputum smear were the most frequently mentioned factors in the majority of the studies. The studies used different measures of association to analyze the factors. Out of the 94 reviewed articles, 11(11.7%) studies applied chi square test. Twenty two (23.4%) studies reported TBDM risk/associated factors using odds ratio, relative risk or hazard ratio. Conversely, 61 (64.9%) studies did not report either associated or risk factors for TBDM coexistence. This might be due to that most of the studies did not have adequate sample size and almost all studies mentioned neither in their objective nor in the limitation part about the risk factors of TBDM comorbidity. The following is a brief thematic description of the associated/ risk factors that were identified in the different studies.

### 1. Socio-demographic and economic factors {#sec016}

A number of studies concluded that both males \[[@pone.0175925.ref018], [@pone.0175925.ref021], [@pone.0175925.ref094]\] and females \[[@pone.0175925.ref076], [@pone.0175925.ref091], [@pone.0175925.ref095]\] were at increased risk for TBDM comorbidity. Men were more likely to develop TBDM comorbidity compared to women \[[@pone.0175925.ref015]\]. Twenty two studies reported that older age increased the risk of TBDM comorbidity \[[@pone.0175925.ref014]--[@pone.0175925.ref015], [@pone.0175925.ref017]--[@pone.0175925.ref019], [@pone.0175925.ref023], [@pone.0175925.ref025]--[@pone.0175925.ref026], [@pone.0175925.ref028], [@pone.0175925.ref030], [@pone.0175925.ref048], [@pone.0175925.ref054], [@pone.0175925.ref056], [@pone.0175925.ref065]--[@pone.0175925.ref067], [@pone.0175925.ref076], [@pone.0175925.ref081], [@pone.0175925.ref086], [@pone.0175925.ref091], [@pone.0175925.ref096], [@pone.0175925.ref100]\]. Urban residence and having an education level beyond primary schooling were associated factors for TBDM comorbid conditions \[[@pone.0175925.ref031], [@pone.0175925.ref069]\]. Place of birth, ethnicity, high-income status and sedentary occupation were risk factors associated with TBDM comorbidity \[[@pone.0175925.ref021], [@pone.0175925.ref026], [@pone.0175925.ref028], [@pone.0175925.ref030], [@pone.0175925.ref048], [@pone.0175925.ref086], [@pone.0175925.ref091], [@pone.0175925.ref094]\].

### 2. Behavioral factors {#sec017}

Illicit drug use, and sedentary lifestyle were reported as behavioral factors associated with TBDM comorbidity \[[@pone.0175925.ref015], [@pone.0175925.ref085]\]. Cigarette smoking \[[@pone.0175925.ref021]\] and being alcohol drinker \[[@pone.0175925.ref023]\] were identified as an increased risk factors for TBDM coexistence. Practicing frequent outdoor activity was reported as a low behavioral risk factor for TBDM comorbidity \[[@pone.0175925.ref030]\].

### 3. Clinical factors {#sec018}

Both lower and higher body mass index (BMI), human immune--deficiency virus (HIV) coinfection, body weight loss and hypertension were reported as associated factors for TBDM comorbidity \[[@pone.0175925.ref015]--[@pone.0175925.ref016], [@pone.0175925.ref021], [@pone.0175925.ref026], [@pone.0175925.ref058], [@pone.0175925.ref065], [@pone.0175925.ref085]\]. Both lower and higher BMI were also reported as an increased risk factor for TBDM comorbidity \[[@pone.0175925.ref028], [@pone.0175925.ref081]\]. Pre-existing and long duration of DM \[[@pone.0175925.ref069], [@pone.0175925.ref081]\], poor glycemic control at the time of TB diagnosis \[[@pone.0175925.ref079]\], patients with liver cirrhosis \[[@pone.0175925.ref021]\] and history of high blood pressure \[[@pone.0175925.ref026]\] were identified as an increased risk factor for the development of TBDM comorbidity. DM with both positive \[[@pone.0175925.ref015]\] and negative \[[@pone.0175925.ref070]\] HIV status- were documented as associated and increased risk factor for TBDM comorbid condition. HIV coinfection and malnutrition were also reported as low risk factor for TBDM comorbidity \[[@pone.0175925.ref072], [@pone.0175925.ref095]\]. HIV coinfection with injection drug use (IDU) or without IDU was reported as low risk factor for TBDM coexistence \[[@pone.0175925.ref088]\]. TBDM comorbid patients were more likely to be PTB case, smear- positive, to have anti-TB drug resistance, to have cavitary lesions on chest x-ray, and to have high alanine transaminase (ALT) level \[[@pone.0175925.ref010], [@pone.0175925.ref025], [@pone.0175925.ref028], [@pone.0175925.ref030], [@pone.0175925.ref048], [@pone.0175925.ref054], [@pone.0175925.ref056], [@pone.0175925.ref088]--[@pone.0175925.ref089], [@pone.0175925.ref072], [@pone.0175925.ref076], [@pone.0175925.ref084], [@pone.0175925.ref088], [@pone.0175925.ref095], [@pone.0175925.ref100]\]. On the contrary, being an extra pulmonary TB (EPTB) case was reported as a low risk factor for TBDM comorbidity \[[@pone.0175925.ref100]\].

### 4. History of DM, TB illness & TB treatment {#sec019}

Having family history of DM, history of TB illness and treatment, experiencing more side effect of anti-TB treatment, type of TB treatment category, treatment for previous TB episode and extension of anti-TB treatment durations were reported as increased risk factor for TBDM comorbidity \[[@pone.0175925.ref023], [@pone.0175925.ref025]--[@pone.0175925.ref026], [@pone.0175925.ref028], [@pone.0175925.ref030], [@pone.0175925.ref054], [@pone.0175925.ref065], [@pone.0175925.ref069], [@pone.0175925.ref076], [@pone.0175925.ref088],[@pone.0175925.ref095]\]. Receiving TB treatment after abandonment was also identified as low risk factor for TBDM comorbidity \[[@pone.0175925.ref100]\].

### 5. Other factors {#sec020}

Contact with TB patient in the family was reported as associated/ increased risk factor for TBDM comorbidity \[[@pone.0175925.ref016], [@pone.0175925.ref069], [@pone.0175925.ref079]\]. Being imprisoned was associated with TBDM comorbidity \[[@pone.0175925.ref015], [@pone.0175925.ref098]\]. TBDM comorbid patients may require hospitalization \[[@pone.0175925.ref088]\]. TBDM patients were more likely to die from TBDM comorbidity \[[@pone.0175925.ref100]\]. Being kept in certain institutions (prisons shelter, orphanage and psychiatric hospital) were documented as low risk factor for TBDM comorbidity \[[@pone.0175925.ref100]\] **([Table 5](#pone.0175925.t005){ref-type="table"}).**

10.1371/journal.pone.0175925.t005

###### Thematic analysis of risk/associated factors for TBDM comorbidity.

![](pone.0175925.t005){#pone.0175925.t005g}

  Risk factor                                                                                        Associated factors                                                                                                                                                      Risk factors                                                                                                                                                                                                                                                                                                                             
  -------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------
  **Socio-demography and economic factors**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  **Sex**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Male                                                                                               \[[@pone.0175925.ref015]\]                                                                                                                                              \[[@pone.0175925.ref018],[@pone.0175925.ref021],[@pone.0175925.ref094]\]                                                                                                                                                                                                                                                                 
  Female                                                                                                                                                                                                                                                                     \[[@pone.0175925.ref076],[@pone.0175925.ref091],[@pone.0175925.ref095]\]                                                                                                                                                                                                                                                                 
  **Age**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Old age                                                                                            \[[@pone.0175925.ref014]--[@pone.0175925.ref015],[@pone.0175925.ref017],[@pone.0175925.ref019],[@pone.0175925.ref065],[@pone.0175925.ref067],[@pone.0175925.ref098]\]   \[[@pone.0175925.ref018],[@pone.0175925.ref023],[@pone.0175925.ref025]--[@pone.0175925.ref026],[@pone.0175925.ref028],[@pone.0175925.ref030],[@pone.0175925.ref048],[@pone.0175925.ref054],[@pone.0175925.ref056],[@pone.0175925.ref076],[@pone.0175925.ref081],[@pone.0175925.ref088],[@pone.0175925.ref091],[@pone.0175925.ref100]\]   
  Urban residence                                                                                    \[[@pone.0175925.ref031]\]                                                                                                                                              \[[@pone.0175925.ref069]\]                                                                                                                                                                                                                                                                                                               
  Education beyond primary schooling                                                                 \[[@pone.0175925.ref031]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Place of birth (Spanish born, Chinese, Philippines)                                                                                                                                                                                                                        \[[@pone.0175925.ref048],[@pone.0175925.ref088],[@pone.0175925.ref094]\]                                                                                                                                                                                                                                                                 
  Ethnicity (Hispanic)                                                                                                                                                                                                                                                       \[[@pone.0175925.ref091]\]                                                                                                                                                                                                                                                                                                               
  High-income status                                                                                                                                                                                                                                                         \[[@pone.0175925.ref026],[@pone.0175925.ref030]\]                                                                                                                                                                                                                                                                                        
  Sedentary occupation                                                                                                                                                                                                                                                       \[[@pone.0175925.ref028]\]                                                                                                                                                                                                                                                                                                               
  Family size                                                                                        \[[@pone.0175925.ref067]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  **Behavioral factors**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Illicit drug use                                                                                   \[[@pone.0175925.ref015]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Sedentary lifestyle                                                                                \[[@pone.0175925.ref085]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Smoking                                                                                                                                                                                                                                                                    \[[@pone.0175925.ref021],[@pone.0175925.ref026]\]                                                                                                                                                                                                                                                                                        
  Current alcohol drinker                                                                                                                                                                                                                                                    \[[@pone.0175925.ref023]\]                                                                                                                                                                                                                                                                                                               
  Frequent outdoor activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \[[@pone.0175925.ref030]\]
  **Clinical factor**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Body weight loss                                                                                                                                                                                                                                                           \[[@pone.0175925.ref021]\]                                                                                                                                                                                                                                                                                                               
  BMI \[17.7 kg/m^2^ (range11.2--31.4), (\<18.6kg/m^2^), (18.5--22.9 kg/m2), and (≥18.5 kg/m^2^)\]   \[[@pone.0175925.ref016]\]                                                                                                                                              \[[@pone.0175925.ref028],[@pone.0175925.ref081]\]                                                                                                                                                                                                                                                                                        
  Overweight or obese                                                                                \[[@pone.0175925.ref058],[@pone.0175925.ref065],[@pone.0175925.ref085]\]                                                                                                                                                                                                                                                                                                                                                                                                                                         
  DM                                                                                                                                                                                                                                                                         \[[@pone.0175925.ref081]\]                                                                                                                                                                                                                                                                                                               
  Long duration of DM                                                                                                                                                                                                                                                        \[[@pone.0175925.ref069],[@pone.0175925.ref081]\]                                                                                                                                                                                                                                                                                        
  Poor glycemic control per unit increase in glycated hemoglobin(HbA1c)                                                                                                                                                                                                      \[[@pone.0175925.ref079]\]                                                                                                                                                                                                                                                                                                               
  DM in HIV negative status                                                                                                                                                                                                                                                  \[[@pone.0175925.ref070]\]                                                                                                                                                                                                                                                                                                               
  HIV coinfection                                                                                    \[[@pone.0175925.ref015]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \[[@pone.0175925.ref072]\]
  HIV with injection drug use                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         \[[@pone.0175925.ref088]\]
  HIV without injection drug use                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      \[[@pone.0175925.ref088]\]
  Malnutrition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        \[[@pone.0175925.ref095]\]
  Liver cirrhosis                                                                                                                                                                                                                                                            \[[@pone.0175925.ref021]\]                                                                                                                                                                                                                                                                                                               
  Hypertension                                                                                       \[[@pone.0175925.ref065]\]                                                                                                                                              \[[@pone.0175925.ref026]\]                                                                                                                                                                                                                                                                                                               
  PTB                                                                                                                                                                                                                                                                        \[[@pone.0175925.ref028],[@pone.0175925.ref048],[@pone.0175925.ref056],[@pone.0175925.ref076]\]                                                                                                                                                                                                                                          
  EPTB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \[[@pone.0175925.ref100]\]
  Drug resistance (in patient with antimicrobial susceptibility test)                                                                                                                                                                                                        \[[@pone.0175925.ref095]\]                                                                                                                                                                                                                                                                                                               
  Positive sputum smear                                                                                                                                                                                                                                                      \[[@pone.0175925.ref025],[@pone.0175925.ref030],[@pone.0175925.ref054],[@pone.0175925.ref084],[@pone.0175925.ref100]\]                                                                                                                                                                                                                   
  Cavitary on chest X-ray                                                                                                                                                                                                                                                    \[[@pone.0175925.ref030],[@pone.0175925.ref054],[@pone.0175925.ref088]\]                                                                                                                                                                                                                                                                 
  Raised serum ALT concentration                                                                                                                                                                                                                                             \[[@pone.0175925.ref072]\]                                                                                                                                                                                                                                                                                                               
  Treatment for diabetes                                                                             \[[@pone.0175925.ref067]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  **History of DM, TB illness & treatment**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Family history of DM                                                                               \[[@pone.0175925.ref085], [@pone.0175925.ref098]\]                                                                                                                      \[[@pone.0175925.ref023],[@pone.0175925.ref025]--[@pone.0175925.ref026],[@pone.0175925.ref028],[@pone.0175925.ref030],[@pone.0175925.ref076]\]                                                                                                                                                                                           
  History of TB illness                                                                                                                                                                                                                                                      \[[@pone.0175925.ref069]\]                                                                                                                                                                                                                                                                                                               
  TB treatment category                                                                              \[[@pone.0175925.ref065]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Experiencing more side effect of anti-TB treatment                                                                                                                                                                                                                         \[[@pone.0175925.ref088]\]                                                                                                                                                                                                                                                                                                               
  To receive TB treatment after abandonment[^\*^](#t005fn001){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \[[@pone.0175925.ref100]\]
  Treatment for a previous TB episode (in patient without antimicrobial susceptibility test)                                                                                                                                                                                 \[[@pone.0175925.ref095]\]                                                                                                                                                                                                                                                                                                               
  Extension of anti-TB treatment duration                                                                                                                                                                                                                                    \[[@pone.0175925.ref054]\]                                                                                                                                                                                                                                                                                                               
  **Other factors**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Contact with TB patient in the family                                                              \[[@pone.0175925.ref016]\]                                                                                                                                              \[[@pone.0175925.ref069],[@pone.0175925.ref079]\]                                                                                                                                                                                                                                                                                        
  Imprisonment                                                                                       \[[@pone.0175925.ref015],[@pone.0175925.ref098]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Hospitalization                                                                                                                                                                                                                                                            \[[@pone.0175925.ref088]\]                                                                                                                                                                                                                                                                                                               
  Institutionalization[^θ^](#t005fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \[[@pone.0175925.ref100]\]
  Outcome of TB: death                                                                                                                                                                                                                                                       \[[@pone.0175925.ref100]\]                                                                                                                                                                                                                                                                                                               

\* ^=^ subjects that discontinued previous TB treatment and returned to treatment

^θ\ =^ being in prison shelter, orphanage and psychiatric hospital

TB = tuberculosis, DM = diabetes mellitus, BMI = body mass index, HIV = human immune-deficiency virus, PTB = pulmonary tuberculosis, EPTB = extra pulmonary tuberculosis, ALT = alanine transaminase, HbA1c = Hemoglobin A1c, kg = kilogram, m^2^ = meter square.

Discussion {#sec021}
==========

This systematic review revealed that the global burden of TBDM comorbidity is high, and is fueled by heterogeneous risk/associated factors. The observed global TBDM comorbidity prevalence in the current systematic review is higher compared to the findings of the previous systematic review conducted in 2010 \[[@pone.0175925.ref011]\]. This might be related to the increasing number of studies addressing TBDM comorbidity in the last six years. A total of 74 studies have been published since 2011 which showed a threefold increase compared to the number of similar studies conducted before 2010. Contrary to the previous systematic review \[[@pone.0175925.ref012]\], where studies from the Africa Regions were not reported, our systematic review showed an increasing number of studies reporting high prevalence of DM among TB patients in some countries of the African Region.

The number of new DM patients identified by screening TB patients varied in the different studies. This variation might be due to differences in the screening methods used and variations in the prevalence of DM in the general population of the respective countries. However, the large proportion of newly identified DM patients suggests the identification of previously undiagnosed DM patients and highlights that screening TB patients for DM in the TB clinic is an important public health intervention \[[@pone.0175925.ref102]\].

The observed prevalence of TB among DM patients in this systematic review is low compared to the previous systematic review findings \[[@pone.0175925.ref011]\]. This might be related to the small number of similar studies conducted, the low sensitivity of diagnostic methods used to detect TB cases and the magnitude of TB prevalence in the studied countries. In addition, the language restriction criteria that we used may have resulted in underreporting bias. Hence, we must be cautious in the interpretation of this finding. The prevalence of TB among DM patients in the studied countries of Asia and the African Regions were high compared to findings of other regions. This may be linked to the fact that countries in these continents are experiencing the fastest increase in DM prevalence along with the high burden of TB and HIV \[[@pone.0175925.ref027], [@pone.0175925.ref072]\].

We analyzed socio-demographic, behavioral, clinical and other factors associated with TBDM comorbidity. Male sex was identified as a risk/associated factor for TBDM comorbidity. Men usually practice smoking cigarettes and alcohol drinking which can predispose them to both diseases conditions \[[@pone.0175925.ref084]\]. Similarly, being women was found to be risk factor for TBDM comorbidity. The reason may be linked to poor health service utilization, care taking role of women for the sick, and influence of estrogen on cytokine production during TB infection that increases the vulnerability of women to TB and consequently to DM \[[@pone.0175925.ref076]\]. Old age was reported as associated/risk factor for TBDM comorbidity. The reason may be related to decrease in immune status in older age individuals that make them more susceptible to develop both TB and DM \[[@pone.0175925.ref048], [@pone.0175925.ref076], [@pone.0175925.ref081]\]. High-income status was also identified as risk factor for the two comorbid condition \[[@pone.0175925.ref026], [@pone.0175925.ref030]\]. Patients with high-income may spend much time in sedentary lifestyle activities than their counter parts and have better access for diagnostic and medical facilities \[[@pone.0175925.ref026]\]. Urban residence was reported as associated/risk factor for the development of TBDM comorbid condition \[[@pone.0175925.ref031], [@pone.0175925.ref069]\]. This might be due to the overcrowded living conditions, less physical activity and consumption of a high calorie rich diet among residents in urban areas \[[@pone.0175925.ref069]\]. In addition, urban residents have better access for the diagnosis of TB and DM.

Behavioral attributes such as tobacco smoking and alcohol drinking are associated with TBDM comorbidity \[[@pone.0175925.ref021], [@pone.0175925.ref023], [@pone.0175925.ref026]\]. Cigarette smoking results in inflammation and oxidative stress in body cells and increases the risk of developing DM \[[@pone.0175925.ref026]**\]**. In contrast, frequent outdoor activity was identified as protective factor for TBDM comorbidity \[[@pone.0175925.ref030]\]. This might be linked to the fact that increased physical activity results in increased peripheral insulin sensitivity which leads to more glucose uptake by body muscles \[[@pone.0175925.ref026]\].

Our systematic review identified various clinical factors associated with TBDM comorbidity. Patients BMI status was identified as increased as well as low risk factor for TBDM comorbid conditions. Previous studies showed that overweight and obesity were risk factors for DM but were protective against TB disease. However, weight loss due to poorly controlled DM and metabolic decomposition takes away this protection and becomes risk factor for TB \[[@pone.0175925.ref030], [@pone.0175925.ref081]\]. Existing DM was the other risk factor for TBDM coexistence. Long term DM is usually associated with uncontrolled DM and can impair the innate and adaptive immune response necessary to counteract the proliferation of TB \[[@pone.0175925.ref028], [@pone.0175925.ref069], [@pone.0175925.ref081]\]. Poor glycemic control and high blood pressure were reported as risk factors for TB among DM patients \[[@pone.0175925.ref079]\]. In resource poor settings, early diagnosis and adequate glycemic control is difficult and poor glycemic control may predispose DM patients to TB disease. In addition, hyperglycemia may provide a conducive environment for bacterial growth and increased virulence of various organisms \[[@pone.0175925.ref069]--[@pone.0175925.ref070], [@pone.0175925.ref079], [@pone.0175925.ref081]\]. The increased risk factor for TBDM related to high blood pressure may be linked to the fact that persons with DM were more likely to develop high blood pressure \[[@pone.0175925.ref026]\].

There is contradictory finding regarding the association of HIV with TBDM comorbidity \[[@pone.0175925.ref015], [@pone.0175925.ref070], [@pone.0175925.ref072], [@pone.0175925.ref088]\]. This might be linked to use of taking cotrimoxazole prophylaxis among HIV positive patients. Cotrimoxazole has been found to cause hypoglycemic effects in some patients \[[@pone.0175925.ref072]\]. The risk factor related to HIV infection could also be related to use of certain antiretroviral drugs that may predispose HIV infected patients to DM \[[@pone.0175925.ref106]\]. Having family history of DM was also identified as associated/risk factors for TBDM comorbidity. Family history of DM is a known risk factor for DM \[[@pone.0175925.ref003]\].

Contact with known TB patients was considered as risk factor for the development of TB among DM patients \[[@pone.0175925.ref016], [@pone.0175925.ref069], [@pone.0175925.ref079]\]. Frequent contact could lead to transmission of TB \[[@pone.0175925.ref069]\]. Patients with history of imprisonment were more likely to be exposed to TBDM comorbid conditions \[[@pone.0175925.ref015], [@pone.0175925.ref098]\].This might indicate that the acquisition of both diseases during imprisonment period is very high \[[@pone.0175925.ref098]\] and might be related to overcrowded and stressful living conditions. It was also reported that TBDM comorbid patients usually become hospitalized \[[@pone.0175925.ref088]\]. DM patient more likely require hospitalization due to glycemic imbalance as a result of infection that may require taking insulin \[[@pone.0175925.ref088]\].

This systematic review has strengths and weaknesses. The comprehensive search strategy applied using multiple electronic databases and the inclusion of a large number of studies covering almost all geographic regions of the world are strengths of the study. Potential limitation of the study could be the exclusion of studies written in other languages except English. However, since our inclusion criteria was very broad and accommodated majority of the studies that assessed the magnitude and associated/risk factors of TBDM comorbidity, the effect of excluding non-English written articles in the generalizability of the study findings would be minimal. We could not be able to report age of study participants due to lack of uniformity in the way it was reported in the reviewed articles. We recommend future studies to address this important variable. One may question why we used prevalence rate to report the findings since all studies reviewed were not cross-sectional studies. However, majority of the articles included in this systematic review reported their findings as prevalence of either TB among DM or DM among TB patients. Some reported as the number of DM or TB patients obtained from screening TB or DM patients. The studies were observational studies and used cross-sectional and descriptive study designs. We thus have used prevalence rate as our effort was to relate it with what the reviewed articles reported. We did not exclude studies based on the level of risk of bias assessment as our main objective was to understand the global picture of the prevalence and associated/risk factors of TBDM comorbidity in a more comprehensive manner. We believe that this may not significantly affect the generalizability of the study as majority of the studies were evaluated as having low-moderate risk of bias. We did not perform metanalysis because of methodological variations observed in the different studies included in our systematic review. The studies varied by type of study design used, methods of DM and TB screening, timing of DM screening and number of enrolled patients.

Conclusion {#sec022}
==========

This systematic review revealed that there is a high burden of DM among TB patients at global level. The highest prevalence of DM among TB patients is observed in the studied countries of Asia, North America and Oceania. On the contrary, the prevalence of TB among DM patients is low globally, but relatively higher in the studied countries of Asia and the African continents. Factors associated with TBDM comorbidity included sex, older age, urban residence, illicit drug use, alcoholism, cigarette smoking, sedentary lifestyle, obesity, HIV coinfection, hypertension, long duration of pre-existing DM, poor glycemic control, being a PTB patient, and family history of DM.

The implementation of the WHO recommended TBDM integrated services is important to address the impact of TBDM comorbidity \[[@pone.0175925.ref006]\]. However, as implementing such a strategy is resource intensive, countries may benefit by first assessing the magnitude and risk/associated factors of TBDM comorbidity before making decisions to undertake such a big initiative.
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